Curr cancer drug targets impact factor
WebCurrent Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang ( UH Drug Discovery Institute). … WebBentham Science Publishers. Bentham Science is a science, technology, and medical publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide.
Curr cancer drug targets impact factor
Did you know?
http://www.eurekaselect.com/ WebColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related deaths in the world with an estimated number of 1.8 million new cases and about 881,000 deaths worldwide in 2024. The epidemiology of CRC varies significantly between different regions in the world …
WebCurrent Cancer Drug Targets is an impact factor journal that covers the full spectrum of cancer drug discovery and development for researchers and oncologists. newsletter banner. ... Researchers can access related articles from current and back volumes by purchasing access to these collections. Subscribers will also have access to new articles ... WebCurrent Cancer Drug Targets is an impact factor journal that covers the full spectrum of cancer drug discovery and development for researchers and oncologists. ... Current Cancer Drug Targets. ISSN (Print): 1568-0096 ... Volume 23, Issue 2, 2024 Review Article Characteristic Hallmarks of Aging and the Impact on Carcinogenesis. Pp: 87-102 Author ...
WebThe graph shows the changes in the impact factor of Current Cancer Drug Targets and its the corresponding percentile for the sake of comparison with the entire literature. … WebAbout Current Drug Targets. Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular …
WebIt is a companion to the highly regarded review journal Current Opinion in Pharmacology (2024 Journal Impact Factor 5.547, CiteScore 9.3) and is part of the Current Opinion …
WebCurrent Cancer Drug Targets. ISSN (Print): 1568-0096 ISSN (Online): 1873-5576. Volume 23 , Issues 11, 2024. This journal supports open access. Back Journal Home Submit Abstracts Submit Manuscripts. Impact Factor. Current: 2.907 5 - Year: 3.516. Ranking & Category. ONCOLOGY 140th of 222; Topic(s) Covered. bimonthly in frenchWebIn this study, we investigate whether miR-34a plays a critical role in the control of cell growth and apoptosis in PC cells. We found that Re-expression (forced expression) of miR-34a inhibits ... bimonthly in mathWebCurrent Cancer Drug Targets publishes original research papers in the field of Biological Sciences, Oncology and Cancer Research and Pharmacology. The journal is directed at … cypark market capWebA systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens. Ramos-Esquivel, Allan; Garita-Rojas, Esteban; Masis-Marroquín, Adriana. Anti-Cancer Drugs. 34 (3):405-412, March 2024. Abstract. bi monthly house paymentsWeb13 rows · About Current Cancer Drug Targets. Current Cancer Drug Targets aims to cover all the latest and ... bimonthly is every 2 weeksWebCurrent Cancer Drug Targets. ISSN (Print): 1568-0096 ISSN (Online): 1873-5576 Volume 23 , Issues 11, 2024. This journal supports open access. Back Journal Home Submit … bimonthly interestWebJul 13, 2024 · Current Neuropharmacology remains the most impactful title from our catalog, over the last year, and Its Impact Factor has increased to 7.708. Another highlight is Current Radiopharmaceuticals ... bimonthly income budget